In the United States Focalyx® is marketed by
Clinical Laserthemia Systems, Focalyx Team up for Prostate Cancer Treatment
(MT Newswires) Clinical Laserthermia Systems (CLS-B.ST), through its US arm, partnered with US-based Focalyx to co-market a focal laser treatment for low-to-intermediate risk prostate cancer.
The partnership combines the Swedish medical equipment company's Tranberg Thermal Therapy System with the Focalyx Fusion image-guidance system, which urology clinics can access through a mobile service provider agreement, according to a Monday release.
The agreement includes training, accessories and on-site support for physicians and staff.
CLS Americas and Focalyx Co-Marketing Agreement for Image-Guided Focal Laser Ablation of Prostate Tumors Using TRANBERG and Focalyx® Fusion Systems.
Minimally Invasive, Outpatient Treatment Designed for Quick Recovery and Low Risk of Unwanted ED and UI Side Effects
Bring prostate cancer treatment into your office!
Join our Focalyx® network, and be part of our breakthrough! Incorporate Focalyx® Fusion technology power & precision into your office and watch both your patients & practice thrive.
MR/US FUSION TARGET PROSTATE CRYOABLATION OPTIMIZING OUTCOMES
